QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
Positive News Sentiment  
NASDAQ:VERV

Verve Therapeutics - VERV Stock Forecast, Price & News

$21.77
-0.65 (-2.90%)
(As of 01/30/2023 04:21 PM ET)
Add
Compare
Today's Range
$21.50
▼
$22.43
50-Day Range
$17.85
▼
$24.00
52-Week Range
$10.70
▼
$43.00
Volume
420,295 shs
Average Volume
586,084 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.17

Verve Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
99.6% Upside
$43.17 Price Target
Short Interest
Bearish
31.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.62mentions of Verve Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$12.97 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.02) to ($2.94) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

652nd out of 1,049 stocks

Pharmaceutical Preparations Industry

330th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

VERV stock logo

About Verve Therapeutics (NASDAQ:VERV) Stock

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Stock News Headlines

January 3, 2023 | finance.yahoo.com
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 | cnbc.com
BMO upgrades this gene-editing play, sees shares returning 65% next year
January 30, 2023 | Investing Trends (Ad)
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
December 5, 2022 | msn.com
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
December 5, 2022 | marketwatch.com
Verve Therapeutics Shares Tumble on FDA Study Hold Update >VERV
December 5, 2022 | finance.yahoo.com
Verve Therapeutics Crashes On The FDA's Long List Of Gene-Editing Concerns
December 2, 2022 | finance.yahoo.com
We're Hopeful That Verve Therapeutics (NASDAQ:VERV) Will Use Its Cash Wisely
November 30, 2022 | msn.com
There are ways to conquer ‘vacation guilt’ in the always-on American workplace
January 30, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 16, 2022 | finance.yahoo.com
SeQure Dx Emerges From Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies for Biopharma Partners, Physicians, and Patients
November 10, 2022 | finance.yahoo.com
The Petri Dish: Biogen's CEO search stalls again; A setback for Verve
November 8, 2022 | apnews.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV
November 7, 2022 | msn.com
Looking Into Verve Therapeutics's Recent Short Interest
November 7, 2022 | finance.yahoo.com
Verve Therapeutics Shares Tumble After FDA Hold On Trial For Elevated Cholesterol Level Candidate
November 7, 2022 | finance.yahoo.com
Verve, Beam Stocks Crash After FDA Halts Plan To Test Gene Editor In People
November 7, 2022 | finance.yahoo.com
Why Verve Therapeutics' Stock Dropped 26.33% on Monday
November 7, 2022 | investorplace.com
Why Is Verve Therapeutics (VERV) Stock Down 28% Today?
November 7, 2022 | msn.com
Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates
November 7, 2022 | seekingalpha.com
Verve sheds 22% as FDA holds trial application for gene editing drug
November 7, 2022 | finance.yahoo.com
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
November 7, 2022 | finance.yahoo.com
Verve Crashes After FDA Halts Plan To Test Gene Editor In People
November 2, 2022 | benzinga.com
LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
October 31, 2022 | finance.yahoo.com
Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn
October 25, 2022 | stocknews.com
2 Cathie Wood Stocks It Would Be Wise to Avoid This Fall
October 22, 2022 | finance.yahoo.com
With stock up 4.7%, Insiders of Verve Therapeutics, Inc. (NASDAQ:VERV) must be wishing they had bought more last year
October 17, 2022 | finance.yahoo.com
Cathie Wood Doubles Down on These 2 Innovation Stocks
October 14, 2022 | finance.yahoo.com
Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition
See More Headlines
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Company Calendar

Last Earnings
11/07/2022
Today
1/30/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VERV
CUSIP
N/A
CIK
1840574
Web
vervetx.com
Phone
617-603-0070
Fax
N/A
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.17
High Stock Price Forecast
$62.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+98.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-120,310,000.00
Net Margins
N/A
Pretax Margin
-15,892.25%
Return on Equity
-38.52%
Return on Assets
-34.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.35
Quick Ratio
19.35

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.42 per share
Price / Book
2.93

Miscellaneous

Outstanding Shares
61,600,000
Free Float
45,341,000
Market Cap
$1.34 billion
Optionable
Not Optionable
Beta
1.44

Key Executives

  • Dr. Sekar Kathiresan M.D.Dr. Sekar Kathiresan M.D. (Age 50)
    Co-Founder, CEO & Director
    Comp: $986.58k
  • Dr. Anthony Philippakis M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Ms. Allison Dorval (Age 46)
    CFO & Principal Accounting Officer
    Comp: $260.93k
  • Dr. Andrew Bellinger M.D.Dr. Andrew Bellinger M.D. (Age 44)
    Ph.D., Chief Scientific Officer & Chief Medical Officer
    Comp: $727.2k
  • Mr. Andrew D. Ashe J.D.Mr. Andrew D. Ashe J.D. (Age 55)
    Pres & COO
  • Dr. Kiran Musunuru M.D.
    M.P.H., Ph.D., Co-Founder & Sr. Scientific Advisor
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Barry S. Ticho FACC (Age 61)
    M.D., Ph.D., Co-Founder
  • Mr. Issi Rozen M.B.A.
    Co-Founder & Strategic Advisor
  • Ms. Margaret Beaudoin (Age 53)
    VP of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VERV Stock - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" VERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VERV, but not buy additional shares or sell existing shares.
View VERV analyst ratings or view top-rated stocks.

What is Verve Therapeutics' stock price forecast for 2023?

5 brokers have issued 1 year target prices for Verve Therapeutics' shares. Their VERV share price forecasts range from $13.00 to $62.00. On average, they predict the company's stock price to reach $43.17 in the next year. This suggests a possible upside of 99.1% from the stock's current price.
View analysts price targets for VERV or view top-rated stocks among Wall Street analysts.

How have VERV shares performed in 2023?

Verve Therapeutics' stock was trading at $19.35 at the start of the year. Since then, VERV stock has increased by 12.0% and is now trading at $21.68.
View the best growth stocks for 2023 here.

When is Verve Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our VERV earnings forecast.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) posted its quarterly earnings results on Monday, November, 7th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.04. The company had revenue of $0.93 million for the quarter, compared to analysts' expectations of $5 million.

When did Verve Therapeutics IPO?

(VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

What is Verve Therapeutics' stock symbol?

Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV."

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.09%) and Sumitomo Mitsui Trust Holdings Inc. (1.99%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan.
View institutional ownership trends.

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verve Therapeutics' stock price today?

One share of VERV stock can currently be purchased for approximately $21.68.

How much money does Verve Therapeutics make?

Verve Therapeutics (NASDAQ:VERV) has a market capitalization of $1.34 billion. The company earns $-120,310,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis.

How many employees does Verve Therapeutics have?

The company employs 113 workers across the globe.

How can I contact Verve Therapeutics?

The official website for the company is vervetx.com. The company can be reached via phone at 617-603-0070 or via email at ir@vervetx.com.

This page (NASDAQ:VERV) was last updated on 1/30/2023 by MarketBeat.com Staff